Comparison of retinal layer thickness and microvasculature changes in patients with diabetic retinopathy treated with intravitreous bevacizumab vs panretinal photocoagulation

Sci Rep. 2022 Jan 28;12(1):1570. doi: 10.1038/s41598-022-05513-3.

Abstract

To compare changes in retinal layers and microvasculature in diabetic retinopathy (DR) patients after bevacizumab therapy and panretinal photocoagulation (PRP). This prospective study divided patients into two groups: patients treated with bevacizumab and those treated with PRP. Patients visited our retinal clinic at 1, 3, and 6 months after treatment. Retinal layer thickness and vessel density (VD) using optical coherence tomography angiography were analyzed. 37 eyes in the bevacizumab group and 36 eyes in the PRP group were enrolled. In the bevacizumab group, the parafoveal RNFL, GCL, and IPL thicknesses significantly decreased (P < 0.001, P = 0.013, and P = 0.017, respectively), whereas the thicknesses in the PRP group showed an increasing tendency over time (P = 0.087, P = 0.005, and P = 0.003, respectively). The VD of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) in the bevacizumab group did not show significant changes, whereas the VD in the PRP group significantly increased over time (both P < 0.001). Additionally, RNFL (P = 0.001) and GCL thicknesses (P = 0.035) were significant factors affecting changes in BCVA, whereas the VDs of SCP and DCP did not. Patients who received bevacizumab therapy did not show a significant change in macular VD, whereas the VD of patients after PRP significantly increased after treatment. The increased macular VD in patients after PRP would be associated with the increased inner retinal layer thickness after treatment, which was significantly related to the impairment in visual acuity.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angiogenesis Inhibitors* / administration & dosage
  • Angiogenesis Inhibitors* / therapeutic use
  • Bevacizumab* / administration & dosage
  • Bevacizumab* / therapeutic use
  • Diabetic Retinopathy* / drug therapy
  • Female
  • Humans
  • Intravitreal Injections*
  • Light Coagulation / methods
  • Male
  • Microvessels / diagnostic imaging
  • Microvessels / drug effects
  • Microvessels / pathology
  • Middle Aged
  • Prospective Studies
  • Retina* / diagnostic imaging
  • Retina* / drug effects
  • Retina* / pathology
  • Retinal Vessels / diagnostic imaging
  • Retinal Vessels / drug effects
  • Retinal Vessels / pathology
  • Tomography, Optical Coherence*
  • Visual Acuity

Substances

  • Bevacizumab
  • Angiogenesis Inhibitors